Ann: Additional Four Instruments Ordered by AstraZeneca, page-8

New to this one, got interested by that comment:

"• 12 APAS® Independence sales to pharmaceutical customers since product launch in Mar-24 underpins the
potential for a cash flow positive result for full FY2"

That's the best way to start investing. The products / service validated by industry giants and the valuation still low. Market always fears a CR after those types of announcements but that's the opportunity to grab shares not too overvalued.

Compared to some other companies in the bio-tech device business such as IPD, this one is really low valued. Of course revenue isn't in the 10s of millions ( yet ) but the costs aren't that high either.

As always, after my initial buy at 2.2c, just seconds later the huge dump to 1.9c. But that's how I play these things, deliberately bringing the sp down just by buying a few. Works 100%. Now sellers, sell down to mid 1c please.

Will hold a core and trade a few, could become a LT play.

GLTA